



## Locations of CEPI-funded additional COVID-19 vaccine clinical research

Lead Partner	CEPI Funding	Overview	Trial Location
Victoria Biomedical Research Institute (VIBRI)	Up to US \$12.5 million	<p><a href="#">COVID-19 vaccine boosters in people living with HIV</a></p> <p>Evaluating the safety and immunogenicity of homologous and heterologous COVID-19 vaccine boosters in adolescents and adults living with HIV.</p>	DRC, Kenya, Rwanda
Oslo University Hospital	Up to US \$3.1 million	<p><a href="#">COVID-19 vaccines in immunosuppressed and transplant patients</a></p> <p>Evaluating the immune responses to COVID-19 vaccination in patients who are immunosuppressed or those who have received an organ transplant and are receiving immunosuppressive medication.</p>	Norway
International Vaccine Institute (IVI)	Up to US \$12.7 million	<p><a href="#">Clinical research to expand access to BBIBP-CorV in Africa</a></p> <p>Evaluating Sinopharm’s BBIBP-CorV COVID-19 vaccine performance in African populations, including populations living with HIV; and as a heterologous regimen with the AstraZeneca vaccine.</p>	Mozambique
MVC	Up to US \$2.3 million	<p><a href="#">Mix-and-match and fractional COVID-19 booster trial</a></p> <p>Evaluating heterologous and fractional booster dose</p>	Taiwan

		combinations of MVC's COVID-19 vaccine, known as MVC-COV1901, with other COVID-19 vaccines developed by AstraZeneca and Moderna. (Co-funded by MVC)	
<b>University of Oxford and NIHR – ComCOV studies</b>	<p>Com-COV2: Up to US \$5 million</p> <p>Com-COV3: Up to US \$3.1 million</p> <p>COV-Boost: Up to US \$9.5 million</p>	<p><b>Mix-and-match and fractional COVID-19 vaccines in key populations</b></p> <p><u>Com-COV2</u> Comparing COVID-19 vaccine schedule combinations at 4-week intervals.</p> <p><u>ComCOV3</u> Evaluating mix-and-match and fractional booster doses of Pfizer and Novavax COVID-19 vaccines in 12-15-year-olds.</p> <p><b>COV-Boost</b> Comparing booster vaccination schedules in adults.</p>	UK
<b>Vaxxinity</b>	Up to US \$9.25 million	<p><u>Mix-and-match COVID-19 booster trial</u></p> <p>Evaluating Vaxxinity's next-generation UB-612 COVID-19 vaccine candidate as a heterologous booster against the original strain and variants of concern including Omicron, following primary schedule with AstraZeneca, Pfizer, Sinopharm and Sinovac.</p>	US, Mexico, Thailand, Vietnam, Philippines
<b>MCRI and PATH</b>	Up to US \$8.7 million	<p><u>Fractional COVID-19 booster doses</u></p> <p>Evaluating the impact of administering reduced booster doses to adults who have received a primary regimen of Pfizer, AstraZeneca, Sinopharm or Sinovac.</p>	Australia, Mongolia, Indonesia
<b>Sabin Vaccine Institute and PATH</b>	Up to US \$6.3 million	<p><u>Fractional COVID-19 booster doses</u></p> <p>Evaluating the safety and immunogenicity of full or fractional booster doses of Pfizer, AstraZeneca or Sinovac vaccines.</p>	Brazil and Pakistan

<p><b>Oxford Vaccine Group UK and Brazil</b></p>	<p>Up to US \$6.4 million</p>	<p><u><a href="#">Fractional COVID-19 booster doses</a></u></p> <p>Evaluating the safety and immunogenicity of fractional heterologous boosters (AstraZeneca or Pfizer) in populations which have previously been vaccinated with Sinovac.</p>	<p>Brazil</p>
<p><b>Aurum Institute</b></p>	<p>Up to US \$10.3 million</p>	<p><u><a href="#">Mix-and-match vaccine strategies in populations living with and without HIV</a></u></p> <p>Evaluating the safety and immunogenicity of mixed vaccine strategies in people living with or without HIV in South Africa. Trial will evaluate Janssen, Pfizer and SII/Novavax in individuals with previously documented COVID-19 infection or as heterologous boosters.</p>	<p>South Africa</p>
<p><b>ANRS   Emerging Infectious Diseases</b></p>	<p>Up to US 8.7 million</p>	<p><b>COVID-19 vaccines in adult and elderly populations</b></p> <p>Comparing the immune response generated by COVID-19 vaccines in adult and elderly populations.</p>	<p>Guinea and Mali</p>